BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics Announces Participation in September Investor Conference

Allogene Therapeutics (ALLO)Allogene TherapeuticsConference / presentation

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the

Related news

ALLOAllogene Therapeutics2026-05-26 12:30 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLOAllogene Therapeutics2026-09-02 12:30 EST

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

LEGNLegend Biotech Corporation2025-12-17 13:00 EST

Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

View all latest news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate...

Recent company news

ALLOAllogene Therapeutics2026-09-02 12:30 EST

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

ALLOAllogene Therapeutics2026-08-31 12:30 EST

Allogene Therapeutics Announces Participation in September Investor Conference

ALLOAllogene Therapeutics2026-08-12 20:05 EST

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-08-04 12:30 EST

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

ALLOAllogene Therapeutics2026-07-29 12:30 EST

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

Stock data

Close
1.73 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States